Abbott and Novo Nordisk Launch Second Semaglutide Brand Extensior in India

Abbott and Novo Nordisk India have partnered to launch Extensior, a second brand of the diabetes drug semaglutide, in India. Abbott will commercialise Extensior, expanding access beyond urban centers using its distribution network, while Novo Nordisk will manufacture the drug. Semaglutide, approved as an adjunct to diet and exercise for type 2 diabetes, helps reduce blood sugar, supports weight loss, and lowers cardiovascular and kidney risks. The collaboration aims to address India's growing diabetes burden, projected to reach over 150 million by 2050.